Mirvie Granted Breakthrough Device Designation For Test To Identify Risk Of Preeclampsia
Executive Summary
Mirvie’s RNA platform can identify 75% of women who develop preeclampsia months before symptoms occur.
You may also be interested in...
Minute Insight: Thermo Fisher Scientific Wins FDA Clearance For Preeclampsia Blood Test
The FDA cleared Thermo Fisher’s in vitro diagnostic for preeclampsia, the leading cause of pregnancy morbidity and mortality, based on results from the PRAECIS study.
Women’s Health Expert Panel Addresses Challenges, Opportunities In Post-Roe Era
After years of underfunding, stigmatization and lack of research, companies working on products and services that address women’s health care are gaining traction. But the sector also faces unique challenges, such as gaining approval for ads on major social media platforms.
HLTH 2022 Roundup: Mirvie, Grail, Biofourmis, Komodo Health, Babson Diagnostics
This year’s annual HLTH meeting drew more than 9,000 people to Las Vegas from 13-16 November and hundreds of exhibitors. In this first part of a two-part roundup, Medtech Insight highlights interviews with C-suite executives at Mirvie, Grail, Biofourmis, Komodo Health and Babson Diagnostics.